Clinical trial of spinal cord injury treatment to continueRSS Feed

Geron Corporation has announced that it has been given clearance by the Food and Drug Administration to continue the world's first human clinical trial of a hESC-based therapy: GRNOPC1 for acute spinal cord injury.

The company announced a plan to re-initiate the Phase I clinical trial of GRNOPC1, a human embryonic stem cell product, in patients with complete thoracic spinal cord injury and to support future expansion of the trial to patients with cervical injuries.

GRNOPC1 is being developed, initially, for spinal cord injury, but Geron is also exploring application for other neurological diseases, including multiple sclerosis, stroke and Alzheimer disease.

Geron expects the clinical trial to be re-initiated in the third quarter of 2010.

Incorporated in the state of Delaware in 1990, Geron has been in business since 1992. Its headquarters and main facilities are located in Menlo Park, California.

It has also completed Phase I clinical trials for two anti-cancer treatments.

News from Serous Law, specialist spinal injury claim solicitors.

New hope for spinal cord injury sufferers

30 October 2009

Adult neurons can still regenerate as long as 15 months after a spinal cord injury, according to new research.A study, published by Cell Press in the October 29th issue of the journal Neuron, highlights...

Read More...

Pioneering back surgery cures woman's paralysis

29 October 2009

A woman paralysed after sneezing can now walk again thanks to pioneering back surgery, which corrected her spinal injury.Victoria Kenny, a solicitor from Chichester, was watching television when she sneezed...

Read More...

3.9m given to spinal cord injury research

28 October 2009

Medical University of South Carolina (MUSC) researcher, James Krause, has been given more than $3.9 million (£2.4 million) for research into the prediction and prevention of life-threatening secondary...

Read More...